Stock Traders Buy Large Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading activity on Monday. Stock investors bought 67,660 call options on the stock. This is an increase of approximately 52% compared to the average daily volume of 44,492 call options.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 11,609 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total value of $169,491.40. Following the completion of the transaction, the chief financial officer now owns 181,469 shares in the company, valued at $2,649,447.40. The trade was a 6.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the business. Sei Investments Co. boosted its stake in shares of Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after buying an additional 37,890 shares during the period. Vanguard Group Inc. grew its holdings in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after acquiring an additional 136,907 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Hims & Hers Health by 239.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock valued at $2,606,000 after purchasing an additional 118,848 shares during the last quarter. SVB Wealth LLC purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth $421,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Hims & Hers Health during the first quarter worth $1,770,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $30.67 on Wednesday. The stock has a market capitalization of $6.70 billion, a price-to-earnings ratio of 69.73 and a beta of 1.06. The business has a 50-day moving average of $20.85 and a 200 day moving average of $19.44. Hims & Hers Health has a 12 month low of $8.09 and a 12 month high of $31.68.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the firm posted ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.